Latest BioArctic News & Updates

See the latest news and media coverage for BioArctic. We track all announcements, press releases, and industry mentions in real time, all in one place.

BioArctic

Research-oriented biopharma company for neurodegenerative diseases

bioarctic.com

Headquarters: Stockholm, Sweden
Founded year: 2003
Company type: Public company
Number of employees: 150–200

Last updated Today

Latest news about BioArctic

In short: BioArctic achieved record 2025 financial results and advanced its Alzheimer's drug Leqembi through multiple global regulatory approvals and sales.

Company announcements

May 29 BioArctic

BioArctic issued 5,000 Class B shares for stock option exercise

Total shares are 88,724,485 with 218,324,449 votes.

May 28 BioArctic

BioArctic AGM approved dividend and re-elected board

Dividend of SEK 2 per share, re-elected board members, and new incentive program introduced.

May 20 BioArctic

BioArctic reports strong Q1 2026 financials with Leqembi milestone

Net revenues SEK 437.6M, operating profit SEK 210.8M, and a EUR 20M milestone payment from Eisai.

May 8 BioArctic

FDA extends Leqembi Iqlik PDUFA date to August 24

Eisai announces three-month extension for sBLA review of subcutaneous starting dose for early Alzheimer’s. No approvability concerns raised.

Media coverage

May 27 Life Science Sweden

Bioarctic praised after successes with Leqembi

"This will become Sweden's leading pharmaceutical company," says co-founder Lars Lannfelt. Now Bioarctic wins the award SvD Business Achievement 2026.

May 25 Yahoo Finance

BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi. According to Eisai's...

May 20 Yahoo Finance

BioArctic Interim Report for the period January - March 2026

Eisai submitted an expanded application for EU approval of intravenous maintenance treatment with Leqembi administered every four weeks The application for marketing authorization for subcutaneous...

May 17 The Wall Street Journal

BioArctic AB Series B

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least...

Never miss news about BioArctic

Track BioArctic and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

BioArctic competitors & trending companies

Browse news for competitors to BioArctic and other trending companies.